Psych Vivas · Old age psychiatry — residential care and systems of care
Residential aged care psychiatry — structured clinical viva
Fellowship viva covering RAC multifactorial assessment, Fossey/WHELD/Husebo non-drug evidence, Schneider mortality, cautious dosing, DART-AD deprescribing, restraint, and liaison.
On this page & tools
Target exams
Interpretation
Reveal interpretation
Working problem: aggression during personal care in RAC dementia — likely multifactorial (pain, approach, environment, possible delirium) with sedation and falls from current PRN antipsychotic use. Standing olanzapine 10 mg is excessive as an opening move in a frail older adult. Prioritise assessment, non-drug redesign of care, pain protocol, and only then consider lowest-dose short-term drug if residual severe risk, with deprescribing plan.[1][2][5]
Structured viva answers
Reveal structured answers
Assessment. Collateral for time course; medical screen (infection, constipation, retention, pain, hypoxia); medication reconciliation; ABC behaviour charting focused on shower triggers; risk (staff injury, resident harm, falls); capacity/proxy for treatment decisions. Exclude Lewy body features before any high-potency antipsychotic.[1]
Non-drug first. Person-centred personal care (two-person calm approach, warmth, privacy, preferred gender of carer, music, shorter showers). Staff training/psychosocial packages: Fossey reduced antipsychotic use without worsening behaviour; WHELD person-centred training and activities improve QoL/agitation metrics. Husebo pain protocol for behavioural disturbance in nursing-home dementia.[3][4][5]
Drug decision. Do not start olanzapine 10 mg standing. If residual severe danger after non-drug measures: document indication, consent/proxy, ECG as indicated, lowest dose (e.g. olanzapine 2.5 mg range if chosen, or alternative lower-risk local formulary agent), short duration, falls monitoring. Name Schneider death risk and Gill observational mortality. Avoid chemical restraint for convenience.[2][8]
Deprescribing. Build review into the plan. DART-AD: continuation not clearly better for many; long-term follow-up raised mortality concerns — trial reduction when stable with monitoring for relapse.[6][7]
Disposition. Optimise in facility with liaison follow-up; hospital if medical instability or unmanageable risk. Educate staff that evidence supports non-drug pathways reducing drug dependence.[1][3]
References
- [1]Kales HC, Gitlin LN, Lyketsos CG Assessment and management of behavioral and psychological symptoms of dementia BMJ, 2015.PMID 25731881
- [2]Schneider LS, Dagerman KS, Insel P Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials JAMA, 2005.PMID 16234500
- [3]Fossey J, Ballard C, Juszczak E, et al. Effect of enhanced psychosocial care on antipsychotic use in nursing home residents with severe dementia: cluster randomised trial BMJ, 2006.PMID 16543297
- [4]Ballard C, Corbett A, Orrell M, et al. Impact of person-centred care training and person-centred activities on quality of life, agitation, and antipsychotic use in people with dementia living in nursing homes: A cluster-randomised controlled trial PLoS Med, 2018.PMID 29408901
- [5]Husebo BS, Ballard C, Sandvik R, et al. Efficacy of treating pain to reduce behavioural disturbances in residents of nursing homes with dementia: cluster randomised clinical trial BMJ, 2011.PMID 21765198
- [6]Ballard C, Lana MM, Theodoulou M, et al. A randomised, blinded, placebo-controlled trial in dementia patients continuing or stopping neuroleptics (the DART-AD trial) PLoS Med, 2008.PMID 18384230
- [7]Ballard C, Hanney ML, Theodoulou M, et al. The dementia antipsychotic withdrawal trial (DART-AD): long-term follow-up of a randomised placebo-controlled trial Lancet Neurol, 2009.PMID 19138567
- [8]Gill SS, Bronskill SE, Normand SL, et al. Antipsychotic drug use and mortality in older adults with dementia Ann Intern Med, 2007.PMID 17548409